Price (90d)
$6.10Signal Score (90d)
103Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $84.28M | $-171.30M | $-1.74 |
| 2024 | $89.15M | $8.00M | $0.08 |
| 2023 | $30.0K | $-54.37M | $-0.57 |
| 2022 | $1.32M | $-34.68M | $-0.87 |
| 2021 | $5.51M | $-20.24M | $-0.70 |
Social Signal Score
Earnings
Mon, Nov 9(in 3 months)
Consensus estimate $-0.34 per share
Typical surprise -12.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.63 vs $-0.48miss
- Fri, May 15$-0.61 vs $-0.53miss
- Mon, Mar 9$-0.42 vs $-0.42beat
- Mon, Nov 10$-0.52 vs $-0.45miss
- Wed, Aug 13$-0.46 vs $-0.41miss
- Wed, May 14$-0.35 vs $-0.35beat
Estimates and results for SPRY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
SPRYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (29)
- Newsnewsfilecorp.com·21h ago·Negative
Kaplan Fox Reminds ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery of the Lead Plaintiff Deadline on October 5, 2026 New York, New York--(Newsfile Corp. - August 14, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE C…
View source ↗ - Newsnewsfilecorp.com·1d ago·Neutral
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY New York, New York--(Newsfile Corp. - August 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"). A class action lawsuit has already bee…
View source ↗ - Newsglobenewswire.com·1d ago·Neutral
The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY).
View source ↗ - Newsseekingalpha.com·1d ago·Positive
ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·1d ago·Positive
ARS Pharmaceuticals Q2 Earnings Call Highlights ARS Pharmaceuticals NASDAQ: SPRY outlined a revised commercial and spending strategy during its second-quarter 2026 earnings call, with new President and CEO Donn Casale emphasizing provider-focused promotion for its neffy intranasal epinephrine product, lower operating expenses and an expected path to cash-flow breakeven by the end of 2027.
View source ↗ - Newszacks.com·1d ago·Negative
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.46 per share a year ago.
View source ↗ - Newsglobenewswire.com·1d ago·Neutral
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed.
View source ↗ - Newsnewsfilecorp.com·1d ago·Negative
… Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY San Diego, California--(Newsfile Corp. - August 13, 2026) - Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clini…
View source ↗ - Newsprnewswire.com·2d ago·Negative
SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026 A securities class action alleges ARS Pharmaceuticals paired specific, confident statements about a July 1, 2026 CVS Caremark formulary date with only generalized risk language, leaving SPRY investors exposed to a 23.9% single-day decline. NEW YORK, Aug. 13, 2026 /PRNewswire/ -- SueWallSt alerts investors in ARS Pharmaceuticals Inc. (NASDAQ: SPRY) that a securit…
View source ↗ - Newsglobenewswire.com·2d ago·Negative
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm New class action for ARS Pharmaceuticals Inc. urges investors to seek recovery for alleged securities fraud violations–lead plaintiff deadline of 10/5/2026
View source ↗ - Newsnewsfilecorp.com·2d ago·Positive
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ARS Pharmaceuticals, Inc. (SPRY) Philadelphia, Pennsylvania--(Newsfile Corp. - August 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). What is The Investigation About?
View source ↗ - Newsnewsfilecorp.com·2d ago·Neutral
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY New York, New York--(Newsfile Corp. - August 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"). A class action lawsuit has already been f
View source ↗ - Newsnewsfilecorp.com·2d ago·Negative
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (SPRY) Who Suffered Losses to Contact the Firm Before October 5, 2026 New York, New York--(Newsfile Corp. - August 12, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE
View source ↗ - Newsnewsfilecorp.com·3d ago·Negative
SPRY CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those wh
View source ↗ - Newsprnewswire.com·3d ago·Negative
SPRY Investors with Losses in Excess of $100K Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
View source ↗ - Newsnewsfilecorp.com·3d ago·Negative
ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - SPRY New York, New York--(Newsfile Corp. - August 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"). A class ac
View source ↗ - Newsprnewswire.com·4d ago·Neutral
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behal
View source ↗ - Newsprnewswire.com·4d ago·Neutral
SPRY DEADLINE: The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
View source ↗ - Newsnewsfilecorp.com·4d ago·Negative
SPRY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi
View source ↗ - Newsnewsfilecorp.com·4d ago·Negative
Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to a Securities Class Action Deadline on October 5, 2026 New York, New York--(Newsfile Corp. - August 10, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period"). CLICK HERE TO JOIN
View source ↗ - Newsbusinesswire.com·5d ago·Neutral
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY LOS ANGELES--(BUSINESS WIRE)---- $SPRY--ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY.
View source ↗ - Newsprnewswire.com·5d ago·Negative
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES, Aug. 10, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange C
View source ↗ - Newsgurufocus.com·5d ago·Neutral
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY PR Newswir
View source ↗ - Newsprnewswire.com·5d ago·Neutral
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY LOS ANGELES, Aug. 10, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPRY dur
View source ↗ - Newsnewsfilecorp.com·6d ago·Neutral
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - August 9, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securiti
View source ↗ - Newsgurufocus.com·6d ago·Negative
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law [url="]Schall, Brown and Schwartz LLP[/url] (âSBSâ), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Ph
View source ↗ - Newsbusinesswire.com·6d ago·Negative
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $SPRY--SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗ - Newsnewsfilecorp.com·7d ago·Negative
Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of an Upcoming Lead Plaintiff Deadline on October 5, 2026 New York, New York--(Newsfile Corp. - August 7, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If yo
View source ↗